At The Clinical Group, our Investment Sales division delivers institutional-grade advisory and execution for healthcare real estate owners and investors nationwide, specializing in medical office buildings (MOBs), ambulatory surgery centers (ASCs), specialty clinics, and acute-care-adjacent assets. With decades of exclusive healthcare transaction experience, we position every asset for maximum value by combining proprietary data—cap rates, reimbursement-driven NOI stability, tenant credit profiles (e.g., investment-grade health systems), and future-proof infrastructure—with a curated buyer universe of REITs (Welltower, Ventas), private equity (Hammes, Anchor Health), and 1031 exchange investors. From confidential marketing and competitive bid processes to sophisticated structuring—sale-leasebacks, joint ventures, portfolio recapitalizations, or forward commitments—we consistently achieve premium pricing and compressed timelines. Whether monetizing a single-tenant net-leased MOB, divesting a multi-market portfolio, or acquiring off-market opportunities aligned with value-based care trends, Clinical Group ensures risk-mitigated, tax-optimized exits and strategic acquisitions that capitalize on healthcare’s resilient cash flows and demographic tailwinds.
Why Choose Clinical Group for Investment Sales?
- Healthcare-Only Focus: No generalist distractions—100% of our transactions involve medical assets, ensuring unmatched depth in clinical infrastructure, regulatory compliance (HIPAA, OSHPD, CMS), and reimbursement analytics.
- Proprietary Data & Modeling: In-house cap rate databases, lease renewal probability models, and patient demographic overlays deliver defensible valuations and superior buyer targeting.
- Curated Institutional Buyer Network: Direct relationships with 200+ active healthcare capital sources, including REITs, PE firms, health systems, and family offices—driving competitive tension and off-market opportunities.
- Creative Deal Structuring: Expertise in sale-leasebacks (preserve occupancy while unlocking equity), forward commitments (lock in pricing pre-construction), JV equity raises, and 1031/up-REIT strategies.
- JV Partnership Integration: Seamlessly transition owners into co-investment roles via structured JV’s – preserving governance, promoting long term alignment and enabling capital recycling without full exit.
- Proven Execution Velocity: Average 75 days marketing-to-contract; 98% close rate on accepted offers through rigorous due diligence prep (normalized NOI, lease abstracts, Phase I ESAs, TI depreciation schedules).
- Confidential & Discreet Process: NDA-gated teasers, controlled bid timelines, and virtual data rooms protect tenant relationships and prevent market leakage.
- Full Lifecycle Support: From pre-sale repositioning (lease audits, TI planning) to post-close 1031 identification and reinvestment advisory.
Contact our Investment Sales team today for a complimentary portfolio valuation, cap rate analysis, and bespoke exit or JV transition strategy.